Skip to main content
Warning Date
    2007-02-05

مضادات الاكتئاب المانعة لإعادة امتصاص السيروتونين الانتقائية (SSRIs) تزيد من خطورة الإصابة بكسر العظام عند كبار السن

2007-02-05

خلفية عن الدراسة:

حالات الاكتئاب والإصابة بالكسور الناتجة عن هشاشة العظام تعتبر من الأمراض الشائعة بين كبار السن، وحيث أن مضادات الاكتئاب المانعة لإعادة امتصاص السيروتونين الانتقائية (SSRIs) تستخدم بشكل شائع لعلاج حالات الاكتئاب فإن العلاقة بين استخدامها اليومي وقابلية حدوث الكسور في العظام غير واضحة.

  • To report sector-related issues

  • Call Centre 19999


Other Warnings

Warning Date
    2007-02-07

Potential hazards of using skin numbing products containing topical anesthetic drugs

2007-02-07

FDA informed consumers and healthcare professionals of the potential hazards of using skin numbing products containing topical anesthetic drugs such as lidocaine, tetracaine, benzocaine, and prilocaine in a cream, ointment, or gel. Numbing products are widely used to numb the skin for medical and cosmetic procedures, and to relieve pain, burning and itching due to a variety of medical conditions. FDA has approved many of these products for these uses. Some of these products must be prescribed by a doctor, others may be purchased without a prescription.

  • To report sector-related issues

  • Call Centre 19999


Other Warnings

Warning Date
    2007-02-07

الصحة تسحب مستحضري(بوهلي وبالي) المبيضين للبشرة لاحتوائهما على زئبق سام

2007-02-07

أوقفت وزارة الصحة مستحضري (Pohli) و(Baly) التي تستخدم لتبييض البشرة وأمرت بحصرهما وسحبهما من الصيدليات المحلية و محلات العطارة ومن الوكيل نفسه نظراً لارتفاع نسبة مادة الزئبق السامة في المنتجين حيث وصلت إلى (38796) جزء في المليون لمستحضر Pohli و(3000) الآف جزء في المليون لمستحضر Baly وما تشكله هذه المادة من مخاطر كبيرة على صحة مستخدمي هذين المستحضرين الغير مسجلين لدى الجهات المختصة في وزارة الصحة.

  • To report sector-related issues

  • Call Centre 19999


Other Warnings

Warning Date
    2007-02-14

Medication Errors in Heparin

2007-02-14

Baxter and FDA notified healthcare professionals of the potential for life threatening medication errors involving two Heparin products, Heparin Sodium Injection 10,000 units/mL, and HEP-LOCK U/P 10 units/mL.
Baxter is aware of fatal medication errors that have occurred when two Heparin products with shades of blue labeling were mistaken for each other. Three infant deaths resulted when the higher dosage Heparin Sodium Injection 10,000 units/mL was inadvertently administered instead of the lower dosage of HEP-LOCK U/P 10 units/mL. The currently marketed

  • To report sector-related issues

  • Call Centre 19999


Other Warnings

Warning Date
    2007-02-20

Indications Cut, Black Box Added on Ketek Label

2007-02-20

The FDA announced the removal of two indications from the labeling for the antibiotic Ketek (telithromycin), as well as the addition of a black-box warning.

Following the recommendations issued by an advisory panel in December, the FDA removed indications for acute bacterial sinusitis and acute bacterial exacerbation of chronic bronchitis from Ketek's label. The drug's sole remaining indication is for the treatment of mild to moderate community-acquired pneumonia.

  • To report sector-related issues

  • Call Centre 19999


Other Warnings

Warning Date
    2007-02-27

Side Effects Seen in Children With Vitiligo Treated With Topical Steroids

2007-02-27

Topical high-potency steroid treatment of vitiligo in children is often successful, but may be associated with systemic effects, Canadian and US researchers report in the February issue of the Journal of the American College of Dermatology.

The treatment repertoire for vitiligo is "somewhat limited," Dr. Elena Pope told Reuters Health, but "high-potency steroids are efficacious in repigmentation of the lesions."

  • To report sector-related issues

  • Call Centre 19999


Other Warnings

Warning Date
    2007-03-19

Cialis (Tadalafil) ,Levitra (Vardenafil hydrochloride) and Viagra (Sildenafil citrate)

2007-03-19

FDA notified healthcare professionals of updated labeling for Cialis, Levitra and Viagra to reflect a small number of post-marketing reports of sudden vision loss, attributed to NAION (non arteritic ischemic optic neuropathy), a condition where blood flow is blocked to the optic nerve. FDA advises patients to stop taking these medicines, and call a doctor or healthcare provider right away if they experience sudden or decreased vision loss in one or both eyes.

  • To report sector-related issues

  • Call Centre 19999


Other Warnings

Warning Date
    2007-04-03

Withdraw pergolide from the market

2007-04-03

FDA notified healthcare professionals and patients that companies that manufacture and distribute pergolide have agreed to withdraw the drug from the market. Pergolide is a dopamine agonist (DA) used with levodopa and carbidopa to manage the signs and symptoms of Parkinson's disease. Results of two new studies showed that some patients with Parkinson's disease treated with pergolide had serious damage to their heart valves when compared to patients who did not receive the drug.

  • To report sector-related issues

  • Call Centre 19999


Other Warnings

Warning Date
    2007-04-11

Life-threatening Effects From Mixing Supplements, Herbs, Over-the-counter Medications And Prescription Drugs

2007-04-11

People are mixing supplements, herbs and over-the-counter medications and prescription drugs to cure themselves of ills, unaware that they could be making themselves sicker, says George Grossberg, M.D., director of the division of geriatric psychiatry at Saint Louis University.

  • To report sector-related issues

  • Call Centre 19999


Other Warnings

Warning Date
    2007-04-11

Inhaled Steroids Linked to Oropharyngeal Side Effects

2007-04-11

Inhaled corticosteroids used to treat asthma can cause a number of oropharyngeal adverse events, including candidiasis and dysphonia, US researchers report in the Annals of Allergy, Asthma, and Immunology for March.

The oropharyngeal side effects that arise with inhaled steroid use can affect adherence to these medications. However, these adverse events have received much less attention than the drugs' systemic side effects, note Dr. Gary S. Rachelefsky from UCLA School of Medicine, and colleagues

  • To report sector-related issues

  • Call Centre 19999


Other Warnings

Subscribe to Drugs